PROCESS FOR THE ISOLATION OF LOVASTATIN

Abstract: There is disclosed a process for the isolation of the hypolipaemic active substance lovastatin from a sample, e.g. fermentation broth, mycelium or filtrate of Aspergillus terreus (ATCC 20542) or Aspergillus oryzae (ATCC 74135) by extraction with butyl acetate. Simultaneously with the concentration of the extract, lactonisation takes place. There follows a direct crystallization of lovastatin in the lactone form from butyl acetate.

Description: PROCESS FOR THE ISOLATION OF LOVASTATIN Technical Field The invention belongs to the field of biotechnology and relates to a process for the isolation of the hypolipaemic active substance lovastatin from a fermentation broth. Lovastatin is produced as a secondary metabolite of the fungus Aspergillus terreus (US 4,231,938) deposited in American Type Culture Collection under Nos. ATCC 20541, ATCC 20542, and Monascus ruber deposited in Fermentation Research In¬ stitute Agency of Industrial Science and Technology, Ministry of International Trade and Industry, Japan (DE 30 06 216 Al) under No. Ferm 4822. Other kinds of microorganisms producing lovastatin are known as well, e.g. a mutant of the microor¬ ganism Aspergillus terreus and Aspergillus oryzae marked ATCC 74135. Lovastatin is chemically l',2',6',7',8a'-hexahydro-3,5-dihydroxy-2',6'-dimethyl-8'-2"- methyl-l"-oxobutoxy)-l-naphtalene heptanoic acid-5-lactone (Stubbs et al., 1986) of the formula (EP 0033 537 Al) Compound I An active form of lovastatin is also an acid, which is chemically l,2,6,8,8a-hexahydro- 3,δ-dihydroxy-l-naphtalene heptanoic acid (Alberts et al., 1980) of the formula (EP 0022478 Al) Compound II The lactone form of lovastatin is used as an agent for reducing cholesterol level in blood (Scott M.G. and Vega G.L., 1985). It inhibits the biosynthesis of mevalonic acid by inhibition of 3-hydroxy-3-methylglutaryl A reductase coenzyme (HMG-CoA reductase, E.C. 1.1.1.34) (Zubay et al., 1984). PriorArt After the completed fermentation, lovastatin is present in the broth in the lactone form (compound I) and in the acid form (compound II). In the isolation process as disclosed in EP 0 033 536 A2, lovastatin is extracted from the broth with ethyl acetate. The extract is concentrated by vacuum distillation. Since lovastatin is present in the lactone form as well as in the acid form and only the lactone is of commercial interest, the acid form should be converted into the lactone. The lactonisation is carried out by the reflux of the concentrate in toluene at 106 °C for 2 hours. After the lactonisation is complete, the solution is concentrated to a small volume. A pure sub¬ stance is obtained by means of purifying the concentrate on columns packed with silica gel, in the presence of solvents such as ethyl acetate or n-hexane. The collected fractions are again concentrated in vacuo and then pure lovastatin crystallizes in the lactone form. Due to the sophisticated multi-step procedure and vigorous conditions applied during the isolation, the yields of lovastatin are generally low. Different solvents, which in part exhibit toxicity, are used such as benzene, toluene, acetonitrile or ethyl acetate. Hence working with these solvents endangers the health of the persons in¬ volved and poses a problem with respect to the environment. Description of the Invention An object of the present invention was to overcome the above deficiencies of the state of the art and to provide a process for isolating lovastatin in an efficient and economic way. In addition, attention should be paid to health aspects of the workers involved in the isolation and to the environment. As a result of extensive search leading to the present invention, the present inventors have found that lovastatin may be easily isolated by extracting lovastatin from a sample with butyl acetate, concentrating the solution and carrying out a crystal¬ lization. In a preferred embodiment the concentration of the solution is carried out under reduced pressure. In a further preferred embodiment concentration is carried out at a temperature above 40 °C with or without reduced pressure. In yet another preferred embodiment the sample of lovastatin is derived from microorganisms, preferably a fungus capable of producing lovastatin. In this case the sample may be the fermentation broth in which the microorganism or the fungus, respectively, has been grown, the mycelium of the fungus or the filtrate. The fungus to be used is not limited and any fungus capable of producing lovastatin may be utilized, with those belonging to the genus Aspergillus, preferably Aspergillus oryzae or Aspergillus terreus, being preferred. In yet another preferred embodiment the fungus is Aspergillus terreus (ATCC 20542) oτApergillus oryzae (ATCC 74135). According to the process of the present invention lovastatin may be obtained ex¬ clusively in the lactone form. It has surprisingly been found that the solvent utilized, i.e. butyl acetate, provides features enabling to achieve this goal. Namely, in the lactonisation process water is released and should be removed from the reaction medium. Since butyl acetate has a higher boiling point and does not substantially form azeotropic mixtures with water under the given conditions, essentially all water formed during the lactonisation process may be removed. By the process according to the present invention it has become possible to substan¬ tially shorten the time for isolating lovastatin. Since butyl acetate may be used to ex¬ tract lovastatin from a sample and at the same time may be utilized for performing the lactonisation, the toxic effects of other solvents may be obviated. The process may be industrially reproduced with the final yields of about 60%, irrespective of lovastatin being produced by microorganisms intracellularly or extracelullarly, in the lactone form or in the acid form. The isolated substance is the same as the substance isolated according to Prior Art processes. The structure was confirmed by IR spectroscopy (Fig.l), mass spectro- scopy (Fig.2), NMR (Fig.3) and UV spectroscopy (Fig.4). The invention is illustrated by the following non-limiting Examples. Example 1 Fermentation broth (1000 ml) obtained by the fermentation of Aspergillus terreus (ATCC 20542) or Aspergillus oryzae (ATCC 74135) and having a pH value of 4.8, an age of 120 hours and a lovastatin content of 300 g/ml (lactone + acid) was acidified with HC1 (36%) to a pH of 3-5. The fermentation broth was then cooled below 20 °C, butyl acetate (500 ml) was added and it was extracted for 4 hours at this tempetra- ture. After the extraction was complete, it was centrifuged and the aqueous and or¬ ganic phases were separated. The mycelium and the aqueous phase were discarded and the organic phase was further treated. It was concentrated by vacuum distillation at a temperature above 40 °C to a volume of 50 ml. Simultaneously with the con¬ centration, the lactonisation process took place as well. The concentrate was then cooled to a temperature below 20 °C and left to stand a few hours so that lovastatin crystallized. The obtained crude product was recrystallized. Lovastatin (170 mg) in the lactone form having a purity above 90% was obtained. Example 2 Fermentation broth (1000 ml) obtained by the fermentation of Aspergillus terreus (ATCC 20542) or Aspergillus oryzae (ATCC 74135) and having a pH value of 4.73, an age of 120 hours and a lovastatin content of 190 /-ig/ml (lactone + acid) in the filtrate and 15 g/ml in the mycelium was acidified with HC1 (36%) to a pH of 3-5. The broth was filtered over Oliver filter. The mycelium was discarded, the filtrate was cooled to a temperature below 20 °C and half the volume of butyl acetate was added. It was ex¬ tracted for 1 hour. Then it was proceeded as in Example 1. Lovastatin (79 mg) in the lactone form having a purity above 90 % was obtained. Example 3 Fermentation broth (1000 ml) obtained by the fermentation of Aspergillus terreus (ATCC 20542) or Aspergillus oryzae (ATCC 74135) and having a pH value value of 4.78, an age of 120 hours and a lovastatin content of 5 μg/ml (lactone + acid) in the filtrate and 300 μ-g/ml in the mycelium was acidified with HC1 (36%) to a pH of 3-5 and centrifuged. The filtrate was discarded, a 4-fold volume of butyl acetate was added to the mycelium and it was cooled below 20 °C. It was extracted for 4 hours. The extraction was followed by centrifuging. The mycelium was discarded and the filtrate treated as in Example 1. Lovastatin (90 mg) in the lactone form having a purity above 90 % was obtained.

Claims: CLAIMS 1. A process for the isolation of lovastatin, characterized in that lovastatin is ex¬ tracted from a sample with butyl acetate, concentrated and left to crystallize. 2. A process according to Claim 1, wherein the solution of lovastatin in butyl acetate is concentrated under reduced pressure. 3. A process according to Claim 1 or 2, wherein the solution of lovastatin in butyl acetate is concentrated at a temperature above 40 °C. 4. A process according to any of the Claims 1 to 3, wherein lovastatin is ex¬ tracted from the fermentation broth, mycelium or filtrate of a microorganism capable of producing lovastatin with butyl acetate. 5. A process according to claim 4, wherein the microorganism capable of producing lovastatin is a fungus. 6. A process according to claim 5, wherein the fungus belongs to the genus Aspergillus. 7. A process according to Qaim 6, wherein the fungus belongs to the genus Aspergillus terreus or Aspergillus oryzae. 8. A process according to Qaim 7, wherein the fungus is Aspergillus terreus (ATCC 20542) or Aspergillus oryzae (ATCC 74135).

Inventors: HAJKO PAVICA, POKORNY MIROSLAV, RADEZ IVAN, VESEL TANJA, HAJKO, PAVICA, Pokorny, Miroslav, RADEZ, IVAN, Vesel, Tanja
Applicants: HAJKO PAVICA, KRKA TOVARNA ZDRAVIL, POKORNY MIROSLAV, RADEZ IVAN, VESEL TANJA, HAJKO, PAVICA, KRKA TOVARNA ZDRAVIL P.O., Pokorny, Miroslav, RADEZ, IVAN, Vesel, Tanja
Application year: 1994
Main classification: C07D309
IPC codes: A61K31, C07D309, C12N1, C12N9, C12N11, C12P7, C12P17